Q4 2024 Earnings Call Transcript March 31, 2025 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.03, ...

Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsAdanna Alexander – IRPhillip Chan - ...

Cytosorbents (NASDAQ:CTSO – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a ...

CytoSorbents Corp (CTSO) reports a 25% increase in Q4 product revenue and outlines plans for a major product launch amidst ...

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the ...

Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and ...

Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention ...

赛托索本特在2024年第四季度表现强劲，产品收入同比增长25%。公司继续在血液净化技术板块保持领先地位，利用其在全球70多个国家的国际影响力。虽然收入未达预期，但运营亏损和调整后EBITDA的改善表明公司财务状况正朝着积极方向发展。

日前，《改善体外循环相关全身炎症反应专家共识》于《中国体外循环杂志》发表，该专家共识聚集了国内体外循环及心脏外科领域相关专家，聚焦体外循环导致的全身炎症反应的应对策略。针对体外循环技术改进与体外循环围术期炎症反应的影响，共识推荐使用细胞因子吸附器（证 ...